西藏药业：上半年净利润同比下降8.96% 拟10派8.81元

Core Viewpoint - Xizang Pharmaceutical (600211) reported a slight increase in revenue for the first half of 2025, but a decline in net profit, indicating potential challenges in profitability despite stable sales growth in its main product [1] Financial Performance - The company's revenue for the first half of 2025 reached 1.651 billion yuan, representing a year-on-year growth of 2.23% [1] - The net profit attributable to shareholders was 567 million yuan, showing a year-on-year decrease of 8.96% [1] - The company plans to distribute a cash dividend of 8.81 yuan per 10 shares (including tax) [1] Product Sales - Sales revenue from the main product, Xinhua Su, amounted to 1.456 billion yuan, reflecting a year-on-year growth of 0.41% [1]